CoChat
Sign Up
Cited by 46

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome

D. Hamlett, Eric, A. Boger, Heather, Ledreux, Aurélie, M. Kelley, Christy, J. Mufson, Elliott, F. Falangola, Maria, N. Guilfoyle, David, A. Nixon, Ralph, Patterson, David, Duval, Nathan, E. Granholm, Ann-Charlotte·2015·Current Alzheimer Research
DOI 10.2174/1567205012666150921095505PMC PMC5034871
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1567205012666150921095505

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 189

  1. [1]Hassold T Sherman S Down syndrome: genetic recombination and the origin of the extra chromosome 21 Clin Genet 57 2 95 100 2000 10735628
  2. [2]Presson AP Partyka G Jensen KM Devine OJ Rasmussen SA McCabe LL Current estimate of Down Syndrome population prevalence in the United States J Pediatr 163 4 1163 8 2013 23885965 PMC4445685
  3. [3]Lott IT Dierssen M Cognitive deficits and associated neurological complications in individuals with Down’s syndrome Lancet Neurol 9 6 623 33 2010 20494326
  4. [4]Head E Silverman W Patterson D Lott IT Aging and down syndrome Curr Gerontol Geriatr Res 2012 412536 2012 22844278 PMC3400297
  5. [6]Lai F Williams RS A prospective study of Alzheimer disease in Down syndrome Arch Neurol 46 8 849 53 1989 2527024
  6. [7]Wisniewski KE Dalton AJ McLachlan C Wen GY Wisniewski HM Alzheimer’s disease in Down’s syndrome: clinicopathologic studies Neurology 35 7 957 61 1985 3159974
  7. [8]Lai F Clinicopathologic features of Alzheimer disease in Down syndrome Prog Clin Biol Res 379 15 34 1992 1409742
  8. [9]Menendez M Down syndrome, Alzheimer’s disease and seizures Brain Dev 27 4 246 52 2005 15862185
  9. [10]Rubinsztein DC Hon J Stevens F Pyrah I Tysoe C Huppert FA Apo E genotypes and risk of dementia in Down syndrome Am J Med Genet 88 4 344 347 1999 10402500
  10. [11]Schliebs R Arendt T The cholinergic system in aging and neuronal degeneration Behav Brain Res 221 2 555 63 2010 21145918
  11. [12]Sanchez MM Moghadam S Naik P Martin KJ Salehi A Hippocampal network alterations in Alzheimer’s disease and Down syndrome: from structure to therapy J Alzheimers Dis 26 3 29 47 2011 21971449
  12. [13]Ferrer I Gullotta F Down’s syndrome and Alzheimer’s disease: dendritic spine counts in the hippocampus Acta Neuropathol 79 6 680 5 1990 2141748
  13. [14]Iulita MF Cuello AC Nerve growth factor metabolic dysfunction in Down’s syndrome brains Brain 137 3 860 72 2014 24519975 PMC3927704
  14. [16]Cataldo AM Petanceska S Terio NB Peterhoff CM Durham R Mercken M Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome Neurobiol Aging 25 10 1263 72 2004 15465622
  15. [17]Wilcock DM Neuroinflammation in the aging down syndrome brain: lessons from Alzheimer’s disease Curr Gerontol Geriatr Res 2012 170276 2012 22454637 PMC3290800
  16. [18]Lott IT Head E Doran E Busciglio J Beta-amyloid, oxidative stress and down syndrome Curr Alzheimer Res 3 5 521 8 2006 17168651
  17. [19]Mann DM Esiri MM The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down’s syndrome J Neurol Sci 89 2–3 169 79 1989 2522541
  18. [21]Head E Powell D Gold BT Schmitt FA Alzheimer’s Disease in Down Syndrome Eur J Neurodegener Dis 1 3 353 364 2012 25285303 PMC4184282
  19. [22]Hunter CL Bimonte-Nelson HA Nelson M Eckman CB Granholm AC Behavioral and neurobiological markers of Alzheimer’s disease in Ts65Dn mice: effects of estrogen Neurobiol Aging 25 7 873 84 2004 15212841
  20. [23]Hunter CL Bimonte-Nelson HA Granholm AC Behavioral comparison of 4 and 6 month-old Ts65Dn mice: age-related impairments in working and reference memory Behav Brain Res 138 2 121 31 2003 12527443
  21. [24]Choi JH Berger JD Mazzella MJ Morales-Corraliza J Cataldo AM Nixon RA Age-dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model J Neurochem 110 6 1818 27 2009 19619138 PMC2744432
  22. [26]Lomoio S Scherini E Necchi D Beta-amyloid overload does not directly correlate with SAPK/JNK activation and tau protein phosphorylation in the cerebellar cortex of Ts65Dn mice Brain Res 1297 198 206 2009 19703431
  23. [27]Cárdenas AM Ardiles AO Barraza N Baéz-Matus X Caviedes P Role of tau protein in neuronal damage in Alzheimer’s disease and Down syndrome Arch Med Res 43 8 645 54 2012 23142525
  24. [28]Hof PR Bouras C Perl DP Sparks DL Mehta N Morrison JH Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down’s syndrome. Quantitative regional analysis and comparison with Alzheimer’s disease Arch Neurol 52 4 379 91 1995 7710374
  25. [29]Mann DM Yates PO Marcyniuk B Alzheimer’s presenile dementia, senile dementia of Alzheimer type and Down’s syndrome in middle age form an age related continuum of pathological changes Neuropathol Appl Neurobiol 10 3 185 207 1984 6234474
  26. [30]Mann DM Yates PO Marcyniuk B Ravindra CR The topography of plaques and tangles in Down’s syndrome patients of different ages Neuropathol Appl Neurobiol 12 5 447 57 1986 2946973
  27. [31]Wisniewski KE Wisniewski HM Wen GY Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome Ann Neurol 17 3 278 82 1985 3158266
  28. [32]Wisniewski HM Rabe A Discrepancy between Alzheimer-type neuropathology and dementia in persons with Down’s syndrome Ann N Y Acad Sci 477 247 60 1986 2949682
  29. [33]Schupf N Sergievsky GH Genetic and host factors for dementia in Down’s syndrome Br J Psychiatry 180 405 10 2002 11983636
  30. [35]Busciglio J Capone G O’Bryan J Gardiner KJ Down syndrome: genes, model systems, and progress towards pharmacotherapies and clinical trials for cognitive deficits Cytogenet Genom Res 141 4 260 71 2013 24008277
  31. [36]Gardiner K Fortna A Bechtel L Davisson MT Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions Gene 318 137 47 2003 14585506
  32. [38]Cooper JD Salehi A Delcroix JD Howe CL Belichenko PV Chua-Couzens J Failed retrograde transport of NGF in a mouse model of Down’s syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion Proc Natl Acad Sci U S A 98 18 10439 44 2001 11504920 PMC56979
  33. [39]Granholm AC Sanders LA Crnic LS Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down’s syndrome Exp Neurol 161 2 647 63 2000 10686084
  34. [40]Holtzman DM Santucci D Kilbridge J Chua-Couzens J Fontana DJ Daniels SE Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome Proc Natl Acad Sci U S A 93 23 13333 8 1996 8917591 PMC24093
  35. [41]Insausti AM Megías M Crespo D Cruz-Orive LM Dierssen M Vallina IF Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of Down syndrome Neurosci Lett 253 3 175 8 1998 9792239
  36. [43]Hunter CL Isacson O Nelson M Bimonte-Nelson H Seo H Lin L Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down’s syndrome Neurosci Res 45 4 437 45 2003 12657457
  37. [44]Seo H Isacson O Abnormal APP, cholinergic and cognitive function in Ts65Dn Down’s model mice Exp Neurol 193 2 469 80 2005 15869949
  38. [45]Haydar TF Blue ME Molliver ME Krueger BK Yarowsky PJ Consequences of trisomy 16 for mouse brain development: corticogenesis in a model of Down syndrome J Neurosci 16 19 6175 82 1996 8815899 PMC6579184
  39. [46]Bambrick LL Krueger BK Neuronal apoptosis in mouse trisomy 16: mediation by caspases J Neurochem 72 4 1769 72 1999 10098888
  40. [47]Davisson MT Schmidt C Akeson EC Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome Prog Clin Biol Res 360 263 80 1990 2147289
  41. [48]Duchon A Raveau M Chevalier C Nalesso V Sharp AJ Herault Y Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome Mamm Genome 22 11–12 674 84 2011 21953411 PMC3224224
  42. [49]Sanders NC Williams DK Wenger GR Does the learning deficit observed under an incremental repeated acquisition schedule of reinforcement in Ts65Dn mice, a model for Down syndrome, change as they age? Behav Brain Res 203 1 137 42 2009 19409933 PMC2700176
  43. [50]Ishihara K Amano K Takaki E Ebrahim AS Shimohata A Shibazaki N Increased lipid peroxidation in Down’s syndrome mouse models J Neurochem 110 6 1965 76 2009 19645748
  44. [51]Shukkur EA Shimohata A Akagi T Yu W Yamaguchi M Murayama M Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome Hum Mol Genet 15 18 2752 62 2006 16891409
  45. [52]Belichenko NP Belichenko PV Kleschevnikov AM Salehi A Reeves RH Mobley WC The “Down syndrome critical region” is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome J Neurosci 29 18 5938 48 2009 19420260 PMC3849469
  46. [53]Sago H Carlson EJ Smith DJ Rubin EM Crnic LS Huang TT Genetic dissection of region associated with behavioral abnormalities in mouse models for Down syndrome Pediatr Res 48 5 606 13 2000 11044479
  47. [54]Lockrow J Boger H Bimonte-Nelson H Granholm AC Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome Behav Brain Res 221 2 610 22 2010 20363261 PMC2928411
  48. [55]Salehi A Delcroix JD Belichenko PV Zhan K Wu C Valletta JS Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration Neuron 51 1 29 42 2006 16815330
  49. [56]Cataldo AM Mathews PM Boiteau AB Hassinger LC Peterhoff CM Jiang Y Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects Am J Pathol 173 2 370 84 2008 18535180 PMC2475775
  50. [57]Cataldo AM Peterhoff CM Troncoso JC Gomez-Isla T Hyman BT Nixon RA Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer’s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations Am J Pathol 157 1 277 86 2000 10880397 PMC1850219
  51. [58]Levine S Saltzman A Levy E Ginsberg SD Systemic pathology in aged mouse models of Down’s syndrome and Alzheimer’s disease Exp Mol Pathol 86 1 18 22 2009 19041304 PMC2659493
  52. [59]Villar AJ Belichenko PV Gillespie AM Kozy HM Mobley WC Epstein CJ Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(171)65Dn and mouse chromosome 12 Mamm Genom 16 2 79 90 2005 15859352
  53. [60]Yu T Li Z Jia Z Clapcote SJ Liu C Li S A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions Hum Mol Genet 19 14 2780 91 2010 20442137 PMC2893810
  54. [61]Zhang L Meng K Jiang X Liu C Pao A Belichenko PV Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits Hum Mol Genet 23 3 578 89 2014 24041763 PMC3888256
  55. [62]Ahmed MM Dhanasekaran AR Tong S Wiseman FK Fisher EM Tybulewicz VL Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain Hum Mol Genet 22 9 1709 24 2013 23349361 PMC3613160
  56. [64]Singh P Schimenti JC Bolcun-Filas E A mouse geneticist’s practical guide to CRISPR applications Genetics 199 1 1 15 2015 25271304 PMC4286675
  57. [65]Driscoll LL Carroll JC Moon J Crnic LS Levitsky DA Strupp BJ Impaired sustained attention and error-induced stereotypy in the aged Ts65Dn mouse: a mouse model of Down syndrome and Alzheimer’s disease Behav Neurosci 118 6 1196 205 2004 15598129
  58. [66]Hyde LA Crnic LS Age-related deficits in context discrimination learning in Ts65Dn mice that model Down syndrome and Alzheimer’s disease Behav Neurosci 115 6 1239 46 2001 11770055
  59. [67]Demas GE Nelson RJ Krueger BK Yarowsky PJ Spatial memory deficits in segmental trisomic Ts65Dn mice Behav Brain Res 82 1 85 92 1996 9021073
  60. [68]Bimonte-Nelson HA Hunter CL Nelson ME Granholm AC Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome Behav Brain Res 139 1–2 47 57 2003 12642175
  61. [69]Demas GE Nelson RJ Krueger BK Yarowsky PJ Impaired spatial working and reference memory in segmental trisomy (Ts65Dn) mice Behav Brain Res 90 2 199 201 1998 9521551
  62. [70]Lockrow J Prakasam A Huang P Bimonte-Nelson H Sambamurti K Granholm AC Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model Exp Neurol 216 2 278 89 2009 19135442 PMC2704550
  63. [71]Fernandez F Garner CC Episodic-like memory in Ts65Dn, a mouse model of Down syndrome Behav Brain Res 188 1 233 7 2008 17950473 PMC3230531
  64. [72]Costa AC Stasko MR Schmidt C Davisson MT Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1) Behav Brain Res 206 1 52 62 2010 19720087 PMC2783207
  65. [73]Stasko MR Costa AC Experimental parameters affecting the Morris water maze performance of a mouse model of Down syndrome Behav Brain Res 154 1 1 17 2004 15302106
  66. [74]Escorihuela RM Vallina IF Martínez-Cué C Baamonde C Dierssen M Tobeña A Impaired short- and long-term memory in Ts65Dn mice, a model for Down syndrome Neurosci Lett 247 2–3 171 4 1998 9655620
  67. [75]Whitney KN Wenger GR Impulsivity and motor activity in aged, male Ts65Dn mice Exp Clin Psychopharmacol 21 5 345 54 2013 24099355
  68. [76]Sabbagh MN Chen K Rogers J Fleisher AS Liebsack C Bandy D Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer’s dementia Alzheimers Dement pii: S1552-5260(15) 84 9 2015 PMC4543530 25849033
  69. [77]Handen BL Cohen AD Channamalappa U Bulova P Cannon SA Cohen WI Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B Alzheimers Dement 8 6 496 501 2012 23102120 PMC3532743
  70. [78]Carducci F Onorati P Condoluci C Di Gennaro G Quarato PP Pierallini A Whole-brain voxel-based morphometry study of children and adolescents with Down syndrome Funct Neurol 28 1 19 28 2013 23731912 PMC3812718
  71. [79]d’Abrera JC Holland AJ Landt J Stocks-Gee G Zaman SH A neuroimaging proof of principle study of Down’s syndrome and dementia: ethical and methodological challenges in intrusive research J Intellect Disabil Res 57 2 105 118 2013 22044507
  72. [80]Jacola LM Byars AW Hickey F Vannest J Holland SK Schapiro MB Functional magnetic resonance imaging of story listening in adolescents and young adults with Down syndrome: evidence for atypical neurodevelopment J Intellect Disabil Res 58 10 892 902 2014 23962356
  73. [81]Hartley SL Handen BL Devenny DA Hardison R Mihaila I Price JC Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome Brain 137 Pt 9 2556 63 2014 24993958 PMC4189400
  74. [82]Imai M Watanabe H Yasui K Kimura Y Shitara Y Tsuchida S Functional connectivity of the cortex of term and preterm infants and infants with Down’s syndrome Neuroimage 85 272 278 2014 23631984
  75. [83]Powell D Caban-Holt A Jicha G Robertson W Davis R Gold BT Frontal white matter integrity in adults with Down syndrome with and without dementia Neurobiol Aging 35 7 1562 9 2014 24582640 PMC3992921
  76. [84]Vega JN Hohman TJ Pryweller JR Dykens EM Thornton-Wells TA Resting-state functional connectivity in individuals with down syndrome and williams syndrome compared with typically developing controls Brain Connect 2015 [Epub ahead of print] PMC4601631 25712025
  77. [85]Chen Y Dyakin VV Branch CA Ardekani B Yang D Guilfoyle DN In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model Neurobiol Aging 30 9 1453 65 2009 18180075 PMC2771203
  78. [86]Ishihara K Amano K Takaki E Shimohata A Sago H Epstein CJ Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome Cereb Cortex 20 5 1131 43 2010 19710359
  79. [87]Santin MD Valabrègue R Rivals I Pénager R Paquin R Dauphinot L In vivo 1H MRS study in microlitre voxels in the hippocampus of a mouse model of Down syndrome at 11.7 T NMR Biomed 27 10 1143 50 2014 25088227
  80. [88]Kaur G Sharma A Xu W Gerum S Alldred MJ Subbanna S Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down’s syndrome J Neurosci 34 15 5099 106 2014 24719089 PMC3983795
  81. [89]Nie X Hamlett ED Granholm AC Hui ES Helpern JA Jensen JH Evidence of altered age-related brain cytoarchitecture in mouse models of down syndrome: a diffusional kurtosis imaging study Magn Reson Imaging 33 4 437 47 2014 25527393 PMC4747671
  82. [90]Jensen JH Helpern JA Ramani A Lu H Kaczynski K Diffusional kurtosis imaging: the quantification of non-gaussian water diffusion by means of magnetic resonance imaging Magn Reson Med 53 6 1432 40 2005 15906300
  83. [91]Lu H Jensen JH Ramani A Helpern JA Three-dimensional characterization of non-gaussian water diffusion in humans using diffusion kurtosis imaging NMR Biomed 19 2 236 47 2006 16521095
  84. [92]Jensen JH Helpern JA MRI quantification of non-Gaussian water diffusion by kurtosis analysis NMR Biomed 23 7 698 710 2010 20632416 PMC2997680
  85. [93]Cheung MM Hui ES Chan KC Helpern JA Qi L Wu EX Does diffusion kurtosis imaging lead to better neural tissue characterization? A rodent brain maturation study Neuroimage 45 2 386 92 2009 19150655
  86. [94]Vanhoutte G Pereson S Delgado Y Palacios R Guns PJ Asselbergh B Diffusion kurtosis imaging to detect amyloidosis in an APP/PS1 mouse model for Alzheimer’s disease Magn Reson Med 69 4 1115 21 2013 23494926
  87. [95]Grinberg F Farrher E Ciobanu L Geffroy F Le Bihan D Shah NJ Non-Gaussian diffusion imaging for enhanced contrast of brain tissue affected by ischemic stroke PLoS One 9 2 e89225 2014 24586610 PMC3937347
  88. [96]Weber RA Hui ES Jensen JH Nie X Falangola MF Helpern JA Diffusional kurtosis and diffusion tensor imaging reveal different time-sensitive stroke-induced microstructural changes Stroke 46 2 545 50 2015 25563646 PMC4418934
  89. [97]Falangola MF Guilfoyle DN Tabesh A Hui ES Nie X Jensen JH Histological correlation of diffusional kurtosis and white matter modeling metrics in cuprizone-induced corpus callosum demyelination NMR Biomed 27 8 948 57 2014 24890981 PMC5297373
  90. [98]Belichenko PV Masliah E Kleschevnikov AM Villar AJ Epstein CJ Salehi A Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome J Comp Neurol 480 3 281 98 2004 15515178
  91. [99]Popov VI Kleschevnikov AM Klimenko OA Stewart MG Belichenko PV Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of Down syndrome J Comp Neurol 519 7 1338 54 2011 21452200
  92. [100]Ábrahám H Vincze A Veszprémi B Kravják A Gömöri É Kovács GG Impaired myelination of the human hippocampal formation in Down syndrome Int J Dev Neurosci 30 2 147 58 2012 22155002
  93. [101]Wisniewski KE Schmidt-Sidor B Postnatal delay of myelin formation in brains from Down syndrome infants and children Clin Neuropathol 8 55 62 1989 2524302
  94. [102]Gardiner KJ Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations Drug Des Develop Ther 9 103 125 2015 PMC4277121 25552901
  95. [103]Lockrow JP Fortress AM Granholm AC Age-related neurodegeneration and memory loss in down syndrome Curr Gerontol Geriatr Res 2012 463909 2012 22545043 PMC3318235
  96. [104]McGeer PL The 12th J. A. F. Stevenson memorial lecture. Aging, Alzheimer’s disease, and the cholinergic system Can J Physiol Pharmacol 62 7 741 54 1984 6149804
  97. [105]Perry E Walker M Grace J Perry R Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 22 6 273 80 1999 10354606
  98. [106]Dunnett SB Everitt BJ Robbins TW The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions Trends Neurosci 14 11 494 501 1991 1726766
  99. [107]Ikonomovic MD Mufson EJ Wuu J Cochran EJ Bennett DA DeKosky ST Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer’s neuropathology J Alzheimers Dis 5 1 39 48 2003 12590165
  100. [108]Isacson O Seo H Lin L Albeck D Granholm AC Alzheimer’s disease and Down’s syndrome: roles of APP, trophic factors and ACh Trends Neurosci 25 2 79 84 2002 11814559
  101. [109]Yates CM Simpson J Gordon A Maloney AF Allison Y Ritchie IM Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down’s syndrome Brain Res 280 1 119 26 1983 6228286
  102. [110]Mann DM Yates PO Marcyniuk B Ravindra CR Pathological evidence for neurotransmitter deficits in Down’s syndrome of middle age J Ment Defic Res 29 Pt 2 125 35 1985 2411933
  103. [111]Contestabile A Fila T Bartesaghi R Contestabile A Ciani E Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down’s syndrome and related neurodegenerative diseases J Neurochem 97 2 515 26 2006 16539660
  104. [112]Kelley CM Powers BE Velazquez R Ash JA Ginsberg SD Strupp BJ Sex differences in the cholinergic basal forebrain in the Ts65Dn mouse model of Down syndrome and Alzheimer’s disease Brain Pathol 24 1 33 44 2014 23802663 PMC4220609
  105. [113]Coppus AM Evenhuis HM Verberne GJ Visser FE Eikelenboom P van Gool WA Early age at menopause is associated with increased risk of dementia and mortality in women with Down syndrome J Alzheimers Dis 19 2 545 50 2010 20110600
  106. [114]Granholm AC Ford KA Hyde LA Bimonte HA Hunter CL Nelson M Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome Physiol Behav 77 2–3 371 85 2002 12419414
  107. [115]Lally G Faull RL Waldvogel HJ Ferrari S Emson PC Calcium homeostasis in ageing: studies on the calcium binding protein calbindin D28K J Neural Transm 104 10 1107 12 1997 9503262
  108. [116]Sutherland MK Wong L Somerville MJ Yoong LK Bergeron C Parmentier M Reduction of calbindin-28k mRNA levels in Alzheimer as compared to Huntington hippocampus Brain Res Mol Brain Res 18 1–2 32 42 1993 8479289
  109. [117]Pappas IS Parnavelas JG Neurotrophins and basic fibroblast growth factor induce the differentiation of calbindin-containing neurons in the cerebral cortex Exp Neurol 144 2 302 14 1997 9168831
  110. [118]Iulita MF Claudio Cuello CA The NGF metabolic pathway in the CNS and its dysregulation in down syndrome and Alzheimer’s disease Curr Alzheimer Res 2015 26391047
  111. [119]Chan-Palay V Alterations in the locus coeruleus in dementias of Alzheimer’s and Parkinson’s disease Prog Brain Res 88 625 30 1991 1726030
  112. [120]Whitehouse PJ Struble RG Hedreen JC Clark AW Price DL Alzheimer’s disease and related dementias: selective involvement of specific neuronal systems CRC Crit Rev Clin Neurobiol 1 4 319 39 1985 2876845
  113. [121]Tomlinson BE Irving D Blessed G Cell loss in the locus coeruleus in senile dementia of Alzheimer type J Neurol Sci 49 3 419 28 1981 7217992
  114. [122]Mann DM Yates PO Marcyniuk B A comparison of changes in the nucleus basalis and locus caeruleus in Alzheimer’s disease J Neurol Neurosurg Psychiatry 47 2 201 3 1984 6707659 PMC1027693
  115. [123]Haglund M Sjöbeck M Englund E Locus ceruleus degeneration is ubiquitous in Alzheimer’s disease: possible implications for diagnosis and treatment Neuropathology 26 6 528 32 2006 17203588
  116. [124]Heneka MT Nadrigny F Regen T Martinez-Hernandez A Dumitrescu-Ozimek L Terwel D Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine Proc Natl Acad Sci U S A 107 13 6058 63 2010 20231476 PMC2851853
  117. [125]Feinstein DL Heneka MT Gavrilyuk V Dello Russo C Weinberg G Galea E Noradrenergic regulation of inflammatory gene expression in brain Neurochem Int 41 5 357 65 2002 12176079
  118. [126]Jardanhazi-Kurutz D Kummer MP Terwel D Vogel K Dyrks T Thiele A Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits Neurochem Int 57 4 375 82 2010 20144675
  119. [127]Kalinin S Gavrilyuk V Polak PE Vasser R Zhao J Heneka MT Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer’s disease Neurobiol Aging 28 8 1206 14 2007 16837104
  120. [128]Lockrow J Boger H Gerhardt G Aston-Jones G Bachman D Granholm AC A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model J Alzheimers Dis 23 3 471 89 2011 21098982 PMC3991557
  121. [129]Counts SE Mufson EJ Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity J Neurochem 113 3 649 60 2010 20132474 PMC2913691
  122. [130]Marien MR Colpaert FC Rosenquist AC Noradrenergic mechanisms in neurodegenerative diseases: a theory Brain Res Brain Res Rev 45 1 38 78 2004 15063099
  123. [131]Wenk GL McGann K Hauss-Wegrzyniak B Rosi S The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer’s disease Neuroscience 121 3 719 29 2003 14568031
  124. [132]Rizk P Salazar J Raisman-Vozari R Marien M Ruberg M Colpaert F The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells Neuropsychopharmacology 31 6 1146 57 2006 16292321
  125. [133]Decker MW McGaugh JL Effects of concurrent manipulations of cholinergic and noradrenergic function on learning and retention in mice Brain Res 477 1–2 29 37 1989 2702490
  126. [134]Harley C Noradrenergic and locus coeruleus modulation of the perforant path-evoked potential in rat dentate gyrus supports a role for the locus coeruleus in attentional and memorial processes Prog Brain Res 88 307 21 1991 1687619
  127. [135]Gibbs ME Summers RJ Role of adrenoceptor subtypes in memory consolidation Prog Neurobiol 67 5 345 91 2002 12234500
  128. [136]Salehi A Faizi M Colas D Valletta J Laguna J Takimoto-Kimura R Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome Sci Transl Med 1 7 7ra17 2009 20368182
  129. [137]Fortress AM Hamlett ED Vazey EM Aston-Jones G Cass WA Boger HA Designer receptors enhance memory in a mouse model of down syndrome J Neurosci 35 4 1343 53 2015 25632113 PMC4308587
  130. [138]Kalinin S Polak PE Madrigal JL Gavrilyuk V Sharp A Chauhan N Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist Antioxid Redox Signal 8 5–6 873 83 2006 16771677
  131. [140]Bosboom JL Stoffers D Wolters ECh Cognitive dysfunction and dementia in Parkinson’s disease J Neural Transm 111 10–11 1303 15 2004 15480840
  132. [141]Asherson P Stes S Nilsson Markhed M Berggren L Svanborg P Kutzelnigg A The effects of atomoxetine on emotional control in adults with ADHD: An integrated analysis of multicenter studies Eur Psychiatry 30 4 511 20 2015 25649490
  133. [143]Beyreuther K Dyrks T Hilbich C Mönning U König G Multhaup G Amyloid precursor protein (APP) and beta A4 amyloid in Alzheimer’s disease and Down syndrome Prog Clin Biol Res 379 159 82 1992 1409743
  134. [144]Cork LC Neuropathology of Down syndrome and Alzheimer disease Am J Med Genet Suppl 7 282 6 1990 2149963
  135. [145]Jiang Y Mullaney KA Peterhoff CM Che S Schmidt SD Boyer-Boiteau A Alzheimer’s-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition Proc Natl Acad Sci 107 4 1630 35 2010 20080541 PMC2824382
  136. [146]Kim S Sato Y Mohan PS Peterhoff C Pensalfini A Rigoglioso A Evidence that the Rab5 effector APPL1 mediates APP-ßCTF induced dysfunction of endosomes in Down syndrome and Alzheimer’s disease Mol Psych 2015 in press PMC4721948 26194181
  137. [147]Cossec JC Simon A Marquer C Moldrich RX Leterrier C Rossier J Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol Biochim Biophys Acta 1801 846 852 2010 20580937
  138. [148]Nyakas C Granic I Halmy LG Banerjee P Luiten PG The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-beta42 with memantine Behav Brain Res 221 2 594 603 2011 20553766
  139. [149]Karuppagounder SS Pinto JT Xu H Chen HL Beal MF Gibson GE Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease Neurochem Int 54 2 111 8 2009 19041676 PMC2892907
  140. [150]Trazzi S Fuchs C Valli E Perini G Bartesaghi R Ciani E The amyloid precursor protein (APP) triplicated gene impairs neuronal precursor differentiation and neurite development through two different domains in the Ts65Dn mouse model for Down syndrome J Biol Chem 288 29 20817 29 2013 23740250 PMC3774353
  141. [151]Trazzi S Fuchs C De Franceschi M Mitrugno VM Bartesaghi R Ciani E APP-dependent alteration of GSK3beta activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome Neurobiol Dis 67 24 36 2014 24636797
  142. [152]Begenisic T Baroncelli L Sansevero G Milanese M Bonifacino T Bonanno G Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome Neurobiol Dis 63 12 9 2014 24269730
  143. [153]Heinen M Hettich MM Ryan DP Schnell S Paesler K Ehninger D Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome Neural Plast 2012 467251 2012 22848851 PMC3405721
  144. [154]Richards SJ Edwards P Dunnett SB Animal models of the neuropathology observed in Alzheimer’s disease and Down syndrome Prog Clin Biol Res 379 245 58 1992 1409748
  145. [156]van Leeuwen FW van Tijn P Sonnemans MA Hobo B Mann DM Van Broeckhoven C Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies Neurology 66 2 Suppl 1 S86 92 2006 16432153
  146. [157]Qian W Jin N Shi J Yin X Jin X Wang S Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) enhances tau expression J Alzheimers Dis 37 3 529 38 2013 23948904
  147. [158]Rachubinski AL Maclean KN Evans JR Bjugstad KB Modulating cognitive deficits and tau accumulation in a mouse model of aging Down syndrome through neonatal implantation of neural progenitor cells Exp Gerontol 47 9 723 33 2012 22776132
  148. [159]German DC Eisch AJ Mouse models of Alzheimer’s disease: insight into treatment Rev Neurosci 15 5 353 69 2004 15575491
  149. [160]King DL Arendash GW Behavioral characterization of the Tg2576 transgenic model of Alzheimer’s disease through 19 months Physiol Behav 75 5 627 42 2002 12020728
  150. [161]Resende R Moreira PI Proença T Deshpande A Busciglio J Pereira C Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease Free Radic Biol Med 44 12 2051 7 2008 18423383
  151. [162]Bilkei-Gorzo A Genetic mouse models of brain ageing and Alzheimer’s disease Pharmacol Ther 142 2 244 57 2014 24362083
  152. [163]Morgan D Amyloid, memory and neurogenesis Exp Neurol 205 2 330 5 2007 17445801
  153. [165]Scholtzova H Wadghiri YZ Douadi M Sigurdsson EM Li YS Quartermain D Memantine leads to behavioral improvement and amyloid reduction in Alzheimer’s-disease-model transgenic mice shown as by micromagnetic resonance imaging J Neurosci Res 86 12 2784 91 2008 18615702 PMC2723808
  154. [166]Lott IT Head E Alzheimer disease and Down syndrome: factors in pathogenesis Neurobiol Aging 26 3 383 9 2005 15639317
  155. [168]Wenk GL McGann K Mencarelli A Hauss-Wegrzyniak B Del Soldato P Fiorucci S Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons Eur J Pharmacol 402 1–2 77 85 2000 10940360
  156. [169]Carnevale D De Simone R Minghetti L Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems CNS Neurol Disord Drug Targets 6 6 388 97 2007 18220778
  157. [170]Zassler B Weis C Humpel C Tumor necrosis factor-alpha triggers cell death of sensitized potassium chloride-stimulated cholinergic neurons Brain Res Mol Brain Res 113 1–2 78 85 2003 12750009
  158. [171]Heneka MT Galea E Gavriluyk V Dumitrescu-Ozimek L Daeschner J O’Banion MK Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer’s disease J Neurosci 22 7 2434 42 2002 11923407 PMC6758307
  159. [172]Appleby BS Cummings JL Discovering new treatments for Alzheimer’s disease by repurposing approved medications Curr Top Med Chem 13 18 2306 27 2013 24059463
  160. [173]Cuello AC Ferretti MT Leon WC Iulita MF Melis T Ducatenzeiler A Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology Neurodegener Dis 7 1–3 96 8 2010 20173335
  161. [174]Hunter CL Bachman D Granholm AC Minocycline prevents cholinergic loss in a mouse model of Down’s syndrome Ann Neurol 56 5 675 88 2004 15468085
  162. [175]Parihar MS Hemnani T Alzheimer’s disease pathogenesis and therapeutic interventions J Clin Neurosci 11 5 456 67 2004 15177383
  163. [176]Smith MA Hirai K Hsiao K Pappolla MA Harris PL Siedlak SL Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress J Neurochem 70 5 2212 5 1998 9572310
  164. [177]Jovanovic SV Clements D MacLeod K Biomarkers of oxidative stress are significantly elevated in Down syndrome Free Radic Biol Med 25 9 1044 8 1998 9870557
  165. [179]Behar TN Colton CA Redox regulation of neuronal migration in a Down Syndrome model Free Radic Biol Med 35 6 566 75 2003 12957649
  166. [180]Bambrick LL Fiskum G Mitochondrial dysfunction in mouse trisomy 16 brain Brain Res 1188 9 16 2008 18061151
  167. [182]Sung S Yao Y Uryu K Yang H Lee VM Trojanowski JQ Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer’s disease FASEB J 18 2 323 5 2004 14656990
  168. [184]Giacobini E Present and future of Alzheimer therapy J Neural Transm Suppl 59 231 42 2000 10961434
  169. [185]Prasher VP Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer’s disease in adults with Down syndrome: implications for the intellectual disability population Int J Geriatr Psychiatry 19 6 509 15 2004 15211527
  170. [186]Kondoh T Kanno A Itoh H Nakashima M Honda R Kojima M Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial Int J Psychiatry Med 41 1 71 89 2011 21495523
  171. [187]Villarroya M García AG Marco JL New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer’s disease Curr Pharm Des 10 25 3177 84 2004 15544507
  172. [188]Scarpini E Scheltens P Feldman H Treatment of Alzheimer’s disease: current status and new perspectives Lancet Neurol 2 9 539 47 2003 12941576
  173. [189]Petersen RC Thomas RG Grundman M Bennett D Doody R Ferris S Vitamin E and donepezil for the treatment of mild cognitive impairment N Engl J Med 352 23 2379 88 2005 15829527
  174. [190]Costa AC Scott-McKean JJ Prospects for improving brain function in individuals with Down syndrome CNS Drugs 27 9 679 702 2013 23821040
  175. [191]Heise I Fisher SP Banks GT Wells S Peirson SN Foster RG Sleep-like behavior and 24-h rhythm disruption in the Tc1 mouse model of Down syndrome Genes Brain Behav 14 2 209 16 2015 25558895 PMC4409853
  176. [192]Heller HC Salehi A Chuluun B Das D Lin B Moghadam S Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors Neurobiol Learn Mem 116 162 71 2014 25463650
  177. [193]Sahún I Marechal D Pereira PL Nalesso V Gruart A Garcia JM Cognition and hippocampal plasticity in the mouse is altered by monosomy of a genomic region implicated in Down syndrome Genetics 197 3 899 912 2014 24752061 PMC4096369
  178. [194]Smith GK Kesner RP Korenberg JR Dentate gyrus mediates cognitive function in the Ts65Dn/DnJ mouse model of Down syndrome Hippocampus 24 3 354 62 2014 24339224 PMC4480980
  179. [195]Galdzicki Z Siarey RJ Understanding mental retardation in Down’s syndrome using trisomy 16 mouse models Genes Brain Behav 2 3 167 78 2003 12931790
  180. [196]Coussons-Read ME Crnic LS Behavioral assessment of the Ts65Dn mouse, a model for Down syndrome: altered behavior in the elevated plus maze and open field Behav Genet 26 1 7 13 1996 8852727
  181. [197]Kleschevnikov AM Belichenko PV Faizi M Jacobs LF Htun K Shamloo M Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists J Neurosci 32 27 9217 27 2012 22764230 PMC3411326
  182. [198]Ash JA Velazquez R Kelley CM Powers BE Ginsberg SD Mufson EJ Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice Neurobiol Dis 70 32 42 2014 24932939 PMC4133151
  183. [199]Tabesh A Jensen JH Ardekani BA Helpern JA Estimation of tensors and tensor-derived measures in diffusional kurtosis imaging Magn Reson Med 65 3 823 36 2011 21337412 PMC3042509
  184. [200]Rueda N Flórez J Martínez-Cué C Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome Neurosci Lett 433 1 22 7 2008 18226451
  185. [201]Costa AC Scott-McKean JJ Stasko MR Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test Neuropsychopharmacology 33 7 1624 32 2008 17700645
  186. [202]Rueda N Llorens-Martín M Flórez J Valdizán E Banerjee P Trejo JL Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome J Alzheimers Dis 21 1 277 90 2010 20421694
  187. [203]Bennett FC McClelland S Kriegsmann EA Andrus LB Sells CJ Vitamin and mineral supplementation in Down’s syndrome Pediatrics 72 5 707 13 1983 6226926
  188. [204]Clark S Schwalbe J Stasko MR Yarowsky PJ Costa AC Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome Exp Neurol 200 1 256 61 2006 16624293
  189. [205]De la Torre R De Sola S Pons M Duchon A de Lagran MM Farré M Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans Mol Nutr Food Res 58 2 278 88 2014 24039182

Cited by

Sorted by citations

Metadata

Authors
D. Hamlett, E., A. Boger, H., Ledreux, A., M. Kelley, C., J. Mufson, E., F. Falangola, M., N. Guilfoyle, D., A. Nixon, R., Patterson, D., Duval, N., & E. Granholm, A.-C.
Venue
Current Alzheimer Research
Publisher
Bentham Science Publishers Ltd.
Published
2015-12-07
Volume
13
Issue
1
Pages
35-52
ISSN
1567-2050
DOI
10.2174/1567205012666150921095505
PMC
PMC5034871
Cited by
46
References
16
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review